These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3323707)

  • 1. [Monoclonal antibodies in pigmented lesions].
    Puig L; Moreno A; Moragas JM
    Med Cutan Ibero Lat Am; 1987; 15(6):481-8. PubMed ID: 3323707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
    Steuhl KP; Rohrbach JM; Knorr M
    Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nevus associated malignant melanomas--diagnostic validation and prognosis].
    Stadler R; Garbe C
    Hautarzt; 1991 Jul; 42(7):424-9. PubMed ID: 1938395
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters.
    Busam KJ; Iversen K; Berwick M; Spagnoli GC; Old LJ; Jungbluth AA
    Mod Pathol; 2000 Apr; 13(4):459-65. PubMed ID: 10786815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pigmented epithelioid melanocytoma.
    Ward JR; Brady SP; Tada H; Levin NA
    Int J Dermatol; 2006 Dec; 45(12):1403-5. PubMed ID: 17184238
    [No Abstract]   [Full Text] [Related]  

  • 6. Melanocytic nevi clinically simulating melanoma.
    Makino E; Uchida T; Matsushita Y; Inaoki M; Fujimoto W
    J Dermatol; 2007 Jan; 34(1):52-5. PubMed ID: 17204102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
    Lampert A; Thomine E; Lauret P; Hemet J
    Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micro-anatomy related antigen expression in melanocytic lesions.
    Meije CB; Mooi WJ; Le Poole IC; Van Muijen GN; Das PK
    J Pathol; 2000 Apr; 190(5):572-8. PubMed ID: 10727983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
    Fröhlich E; Mack AF; Garbe C; Klessen C
    Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of the diagnosis of pigmented tumors of the skin and factors leading to a decision to excise. Dermatologists of the Postgraduate Association of Haute-Normandie].
    Collas H; Delbarre M; De Preville PA; Courville P; Neveu C; Dompmartin A; Balguerie X; Lemaistre B; Rzeznik JC; Thiebot B; Boullie MC; Bravard P; Michel Y; Krug M; Le Corvaisier-Pieto C; Young P; Thomine E; Boivin C; Ziade J; Pellerin A; Hellot MF; Leroy D; Lauret P; Benichou J; Joly P
    Ann Dermatol Venereol; 1999; 126(6-7):494-500. PubMed ID: 10495858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Principles of dermatoscopy of pigmented skin lesions.
    Stolz W; Semmelmayer U; Johow K; Burgdorf WH
    Semin Cutan Med Surg; 2003 Mar; 22(1):9-20. PubMed ID: 12773010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosing and treating congenital melanocytic nevus simulating malignant melanoma.
    Kovach R; Hochberg J; Ardenghy M; Deangelis R; Welton W
    W V Med J; 1996; 92(4):191-3. PubMed ID: 8772404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
    Nasr MR; El-Zammar O
    Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis of pigmented skin lesions: how to recognize a malignant melanoma].
    Giard RW; Neumann HA
    Ned Tijdschr Geneeskd; 2004 Nov; 148(46):2261-7. PubMed ID: 15584540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential expression of microtubule-associated protein 2 in melanocytic skin lesions.
    Gambichler T; Rotterdam S; Radkowski K; Altmeyer P; Kreuter A
    Am J Clin Pathol; 2009 May; 131(5):710-4. PubMed ID: 19369632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000.
    Lehmann JM; Holzmann B; Breitbart EW; Schmiegelow P; Riethmüller G; Johnson JP
    Cancer Res; 1987 Feb; 47(3):841-5. PubMed ID: 3542195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi.
    Friedman RJ; Rigel DS; Kopf AW; Lieblich L; Lew R; Harris MN; Roses DF; Gumport SL; Ragaz A; Waldo E; Levine J; Levenstein M; Koenig R; Bart RS; Trau H
    Arch Dermatol; 1983 Jun; 119(6):455-62. PubMed ID: 6859885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues.
    Real FX; Houghton AN; Albino AP; Cordon-Cardo C; Melamed MR; Oettgen HF; Old LJ
    Cancer Res; 1985 Sep; 45(9):4401-11. PubMed ID: 4028024
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens.
    Natali PG; Bigotti A; Cavaliere R; Nicotra MR; Ferrone S
    J Natl Cancer Inst; 1984 Jul; 73(1):13-24. PubMed ID: 6376904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.